Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2023-10-01
2024-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hypoglycemic and Hyperglycemic Disorders
NCT03448965
Frequency of Neonatal Hyperglycemia
NCT06647537
Effects of a Hypoglycemia Protocol With Glucose Gel on Neonatal Intensive Care Unit (NICU) Admission
NCT04085978
To Examine if the Mother's Glucose Levels and Glucose Levels in the Blood Can Predict Cord Hypoglycemia in Newborns at Risk.
NCT02838875
Effect of Antenatal Corticosteroids on Neonatal Hypoglycemia
NCT06716918
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
One of the clinical presentations that raises red flags of inborn error of metabolism is persistent or recurrent hypoglycemia. However recognizing hypoglycemia in the newborn may be difficult, because the symptoms of hypoglycemia (i.e., lethargy, poor feeding, hypothermia, and seizures) are non specific. Frequent blood sugar determinations are often required to confirm the suspicion of hypoglycemia. Because inborn errors of metabolism are a relatively infrequent cause of neonatal hypoglycemia, other diagnostic possibilities should be investigated concurrently.
The first possibility to consider is neonatal stress secondary to perinatal asphyxia, hypothermia, or intrauterine malnutrition (e.g., placental abnormalities, prematurity, multiple gestations). The second consideration is the possibility of a hormonal abnormality affecting insulin regulation. The inborn errors of metabolism associated with insulin dysregulation include 3-hydroxacyl-CoA dehydrogenase (HADH ) deficiency and hyperammonemia/hyperinsulinism (HA/HI) syndrome, both of which are diazoxide-responsive.The third possibility to consider is a malformation syndrome, specifically including those syndromes associated with hormonal dysregulation such as Beckwith-Wiedemann syndrome. The fourth possibility is that the patient has a severe hepatocellular or cirrhotic liver disease that leads non specifically to fasting hypoglycemia.
Hypoglycemia may be associated with five categories of inborn errors of metabolism: fatty acid oxidation defects gluconeogenesis defects, glycogen storage diseases, ketogenesis defects, and organic acidemias . The diagnostic approach to hypoglycemia, therefore, must give consideration to entities belonging to each of these categories. Usually, Krebs cycle defects and mitochondrial disorders do not produce hypoglycemia, but these defects should be considered when other evidence points in their direction.
The diagnostic approach must quickly narrow the field of possible diagnoses so that specific treatment can be instituted. The classic approaches to the differential diagnosis of hypoglycemic disorders in children are the fasting study and specialized challenge tests. These studies are, however, not feasible in newborn infants because of the significant risks and technical difficulties associated with performing such studies and because of the lack of control data derived from normal neonates. Alternatively, efforts to determine the cause of hypoglycemia in the newborn infant should include hormonal and biochemical studies before and after feeding and especially during an acute episode of hypoglycemia. Definitive diagnosis might have to be postponed several months until the child is old enough to tolerate a formal fasting study or specialized in vitro cell studies.
An algorithm for diagnosing the disorders that cause neonatal hypoglycemia can be generated from the results of the following studies: blood electrolytes and pH, plasma and urinary ketones, plasma free fatty acids, blood lactate and pyruvate, blood ammonia, liver function tests, plasma and urinary carnitine and acylcarnitine analysis, and urinary organic acids. A specific diagnosis might not be made by these studies, but they are necessary for providing a provisional diagnosis that can be confirmed by specific enzyme analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Sex : Both genders .
3. Full Term infant ≥ 37 completed weeks.
4. Persistent hypoglycemia (Blood glucose level ≤ 45 mg/dl/2,5 mmol /L) for more than one reading and not responding to IV fluids and /or oral feeding.
Exclusion Criteria
2. Newborn with surgical problems.
1 Day
28 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amany Mohammed Bakry Hassan
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Neonatal hypoglycemia
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.